HLB Co., Ltd. (KOSDAQ:028300)
South Korea
· Delayed Price · Currency is KRW 57,800
+800 (1.40%)
May 9, 2025, 3:30 PM KST
HLB Co., Ltd. Revenue
In the year 2024, HLB Co., Ltd. had annual revenue of 68.13B KRW with 58.80% growth. HLB Co., Ltd. had revenue of 25.22B in the quarter ending December 31, 2024, with 179.62% growth.
Revenue
68.13B
Revenue Growth
+58.80%
P/S Ratio
111.29
Revenue / Employee
425.79M
Employees
160
Market Cap
7,581.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 68.13B | 25.23B | 58.80% |
| Dec 31, 2023 | 42.90B | -136.81B | -76.13% |
| Dec 31, 2022 | 179.71B | 109.88B | 157.37% |
| Dec 31, 2021 | 69.83B | 13.65B | 24.30% |
| Dec 31, 2020 | 56.18B | 17.76B | 46.22% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| PharmaResearch | 350.12B |
| Peptron | 3.15B |
| LigaChem Biosciences | 125.90B |